Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 10Neoplasms 5Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Solid Tumors 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Solid Tumor 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Noonan Syndrome 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Neoplasm Metastasis 1Multiple Myeloma 1Microsatellite Unstable Colorectal Cancer 1Lung Neoplasms 1Lung Diseases 1Leukemia, Myelomonocytic, Chronic 1

Interventions

cobimetinib 1atezolizumab 1Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Mucinous × cobimetinib × Clear all
NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

M.D. Anderson Cancer Center

Phase 2 Completed
49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡